A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD.

Kidney Int Rep · 2026 · PMC12860910 · PMID 41630895

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Efficacy Ratio to Baseline of UACR Over Time Finerenone led to a greater reduction in UACR from baseline to month 4 that was nominally significant versus placebo, irrespective of concomitant SGLT-2i and/or GLP-1RA use at baseline ( Figure 1 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.